Ensysce Biosciences, Inc. - Common Stock (ENSC)

~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~

~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~

Rapid Dose Therapeutics (CSE: DOSE; OTCQB: RDTCF ), a biotechnology and drug delivery innovation company, is accelerating clinical validation of its proprietary QuickStrip™ oral thin film delivery system through expanded cannabinoid research and a high-profile study supported by the National Football League (NFL) .

Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms

~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics and present on commercial excellence ~

~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~

~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~

~ New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~

PF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market Launch

~ Engineered to Deliver Potent Pain Relief with Unique, Built-In, Abuse Protection ~

~ New U.S. Patent Extends Protection Through 2042 ~

~ FDA Response Streamlines Path to Commercial Production of PF614~

~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~

~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~

~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~

~ Experts Spotlight TAAP™ and MPAR® as Next-Generation Solutions for Severe Pain ~

~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~

Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval

~ Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505(b)(2) Regulatory Strategy ~

~ FDA Protocol Review Completed ~

~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~

~ Pain Management, RE-Invented: A New Era for Analgesia ~

Receives U.S. Patent for Groundbreaking Treatment for Opioid Use Disorder

~ Advanced Preparation for New Drug Application ~

SAN DIEGO, CA / ACCESS Newswire / April 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 630,376 shares of common stock of the Company originally issued in March 2025, having an exercise price of $3.24 per share. The shares of common stock issued upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (No. 333-286580). The gross proceeds to the Company from the exercise of the warrants were approximately $2.2 million, prior to deducting placement agent fees and estimated offering expenses.